Advertisement
Canada markets open in 20 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7323
    +0.0000 (+0.00%)
     
  • CRUDE OIL

    84.41
    +0.84 (+1.01%)
     
  • Bitcoin CAD

    87,470.66
    +1,316.33 (+1.53%)
     
  • CMC Crypto 200

    1,385.74
    -10.79 (-0.77%)
     
  • GOLD FUTURES

    2,357.10
    +14.60 (+0.62%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.6820
    -0.0240 (-0.51%)
     
  • NASDAQ futures

    17,728.50
    +161.00 (+0.92%)
     
  • VOLATILITY

    15.57
    +0.20 (+1.30%)
     
  • FTSE

    8,115.12
    +36.26 (+0.45%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6831
    +0.0010 (+0.15%)
     

Incyte Has Diversified Its Revenues across Multiple Product Lines

Incyte Has Diversified Its Revenues across Multiple Product Lines

Incyte (INCY) expects to report GAAP (generally accepted accounting principles) and non-GAAP revenues in the range of $80 million to $85 million from the sale of Iclusig in fiscal 2018. In June 2016, Incyte entered a licensing agreement with Ariad Pharmaceuticals for the development and commercialization of kinase inhibitor, Iclusig, in the European Union and 22 other countries.